Universal Brain

Executive Summary

Universal Brain is a San Francisco-based precision psychiatry company founded in 2021 that aims to transform depression diagnosis and treatment using objective, brain-based patient classifications called neurotypes. By translating cutting-edge clinical neuroscience research, the company seeks to identify distinct subtypes of depression and match patients to more effective therapies. Although still in early stages with no disclosed funding or clinical milestones, Universal Brain addresses a critical unmet need in mental healthcare, where subjective diagnosis often leads to trial-and-error treatment. The company's approach leverages reliable brain function indicators to create a more personalized and data-driven psychiatry paradigm, potentially improving outcomes for millions suffering from depression. If successful, Universal Brain could become a leader in the emerging field of precision psychiatry, though execution risks and the need for extensive clinical validation remain.

Upcoming Catalysts (preview)

• Q4 2026Series A funding announcement70% success
• Q1 2027Initial proof-of-concept clinical data from pilot study55% success
• TBDKey partnership with major academic medical center or pharma45% success